Dolatrai M Vyas

Location:

New York, NY

Industry:

Pharmaceuticals

Work:

Spectrum Pharmaceuticals
Member of the Board of Directors
Dinesh Vyas
Independant Pharmaceuticals R and D Consultant
Bristol-Myers Squibb 1999 - 2011
Distinguished Research Fellow , Oncology Discovery Chemistry
Bristol-Myers Squibb 1991 - 1999
Director: Natural Products and Antitumor Chemistry
Bristol-Myers Squibb 1985 - 1991
Associate Director, Antitumor Chemistry

Education:

Queen's University 1972 - 1980
Queen's University 1967 - 1972
Doctorates, Doctor of Philosophy, Organic Chemistry University of Nairobi 1964 - 1967

Skills:

Lead Change

US Patent:

6455575, Sep 24, 2002

Filed:

Jun 6, 1997

Appl. No.:

08/870794

Inventors:

Jerzy Golik - Southington CT
Dolatrai Vyas - Madison CT
John J. Wright - Guilford CT
Henry Wong - Durham CT
John F. Kadow - Wallingford CT
John K. Thottathil - Robbinsville NJ
Wen-Sen Li - Marlboro NJ
Murray A. Kaplan - Syracuse NY
Robert K. Perrone - Liverpool NY
Mark D. Wittman - Cheshire CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31337

US Classification:

514449, 549510, 549511

Abstract:

The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.

US Patent:

7102003, Sep 5, 2006

Filed:

Jun 21, 2005

Appl. No.:

11/157460

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Harold Mastalerz - Guilford CT, US
Jean-Paul Daris - St-Hubert, CA
Pierre Dextraze - Laprarie, CA
Philippe Lapointe - Greenfield Park, CA
Edward H. Ruediger - Greenfield Park, CA
Dolatrai M. Vyas - Madison CT, US
Guifen Zhang - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53
A61P 35/00

US Classification:

544183, 514243

Abstract:

The present invention provides compounds of formula IThe compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7442700, Oct 28, 2008

Filed:

Jun 27, 2006

Appl. No.:

11/426693

Inventors:

Harold Mastalerz - Guilford CT, US
Dolatrai M. Vyas - Madison CT, US
George L. Trainor - Wilmington DE, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 403/12
C07D 403/14
C07D 487/04
A61K 31/53
A61P 19/02
A61P 35/00

US Classification:

514243, 544183

Abstract:

The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.

US Patent:

7534792, May 19, 2009

Filed:

Jul 5, 2007

Appl. No.:

11/773466

Inventors:

Mark D. Wittman - Wallingford CT, US
Harold Mastalerz - Guilford CT, US
Kurt Zimmermann - Durham CT, US
Mark G. Saulnier - Newington CT, US
Upender Velaparthi - Cheshire CT, US
Dolatrai M. Vyas - Madison CT, US
Guifen Zhang - Wallingford CT, US
Walter Lewis Johnson - Waterbury CT, US
David B. Frennesson - Naugatuck CT, US
Xiaopeng Sang - Glastonbury CT, US
Peiying Liu - Madison CT, US
David R. Langley - Meriden CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 403/12
C07D 403/14
A61K 31/53
A61P 19/02
A61P 35/00

US Classification:

514243, 544183

Abstract:

The invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

US Patent:

7879855, Feb 1, 2011

Filed:

Mar 26, 2009

Appl. No.:

12/411724

Inventors:

Mark D. Wittman - Wallingford CT, US
Harold Mastalerz - Guilford CT, US
Kurt Zimmermann - Durham CT, US
Mark G. Saulnier - Newington CT, US
Upender Velaparthi - Cheshire CT, US
Dolatrai M. Vyas - Madison CT, US
Guifen Zhang - Wallingford CT, US
Walter Lewis Johnson - Waterbury CT, US
David B. Frennesson - Naugatuck CT, US
Xiaopeng Sang - Glastonbury CT, US
Peiying Liu - Madison CT, US
David R. Langley - Meriden CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/53
A61P 35/00
C07D 487/04
C07D 401/14
A61P 19/02

US Classification:

514243, 544183

Abstract:

The invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

US Patent:

8212031, Jul 3, 2012

Filed:

Mar 4, 2009

Appl. No.:

12/920511

Inventors:

Upender Velaparthi - Cheshire CT, US
Dolatrai M. Vyas - Madison CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 253/08

US Classification:

544183, 514243

Abstract:

The invention provides compounds of formula IThe formula I compounds inhibit protein kinase activity thereby making them useful as anticancer agents.

US Patent:

8592579, Nov 26, 2013

Filed:

Aug 7, 2012

Appl. No.:

13/568750

Inventors:

Mark D. Wittman - Wallingford CT, US
Harold Mastalerz - Guilford CT, US
Kurt Zimmermann - Durham CT, US
Mark G. Saulnier - Higganum CT, US
Upender Velaparthi - Cheshire CT, US
Dolatrai M. Vyas - Madison CT, US
Guifen Zhang - Wallingford CT, US
Walter Lewis Johnson - Waterbury CT, US
David B. Frennesson - Naugatuck CT, US
Xiaopeng Sang - Glastonbury CT, US
Peiying Liu - Madison CT, US
David R. Langley - Meriden CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/14
A61K 31/53
A61P 35/00

US Classification:

544183, 514243

Abstract:

The invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

US Patent:

20090062288, Mar 5, 2009

Filed:

Oct 28, 2008

Appl. No.:

12/260051

Inventors:

Harold Mastalerz - Guilford CT, US
Dolatrai M. Vyas - Madison CT, US
George L. Trainor - Wilmington DE, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US

International Classification:

A61K 31/53
C07D 253/10
A61P 35/00

US Classification:

514243, 544183

Abstract:

The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.